Cargando…

Correction to: An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients

Detalles Bibliográficos
Autores principales:	Wallenburg, Eveline, ter Heine, Rob, Schouten, Jeroen A., Raaijmakers, Jelmer, ten Oever, Jaap, Kolwijck, Eva, Burger, David M., Pickkers, Peter, Frenzel, Tim, Brüggemann, Roger J. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439970/ https://www.ncbi.nlm.nih.gov/pubmed/35947361 http://dx.doi.org/10.1007/s40262-022-01165-8

Ejemplares similares

An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients
por: Wallenburg, Eveline, et al.
Publicado: (2022)

Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility
por: Gieling, Emilie M., et al.
Publicado: (2020)

High unbound flucloxacillin fraction in critically ill patients
por: Wallenburg, Eveline, et al.
Publicado: (2021)

Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy
por: Workum, J D, et al.
Publicado: (2020)

612. Pharmacokinetics of Piperacillin-Tazobactam in Patients with Severe Infections
por: Rodríguez-Báez, Ana S, et al.
Publicado: (2022)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese Patients
por: Veillette, John J., et al.
Publicado: (2021)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections
por: Kim, Yong Kyun, et al.
Publicado: (2016)

Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn
por: Selig, Daniel J., et al.
Publicado: (2022)

DRESS syndrome induced by piperacillin-tazobactam
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy
por: Álvarez, José C, et al.
Publicado: (2013)

Enterobacter endophthalmitis: Treatment with intravitreal tazobactam- piperacillin
por: Singh, Trehan Hemant, et al.
Publicado: (2007)

Piperacillin-tazobactam-induced hypokalemia and metabolic alkalosis
por: Zaki, Syed Ahmed, et al.
Publicado: (2011)

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
por: Pilmis, Benoit, et al.
Publicado: (2017)

Piperacillin/tazobactam: Eosinophilic-pneumonia: case report
Publicado: (2021)

Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients
por: Martial, Lisa C., et al.
Publicado: (2017)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation
por: Kim, Yong Kyun, et al.
Publicado: (2022)

Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
por: Felton, T W, et al.
Publicado: (2014)

Tazobactam and piperacillin-induced thrombocytopenia: A case report
por: CHEN, HONG, et al.
Publicado: (2016)

Piperacillin/Tazobactam as Cause of Acute Generalized Exanthematous Pustulosis
por: Kyriakou, Aikaterini, et al.
Publicado: (2019)

Meropenem/piperacillin/tazobactam: Drug resistance: case report
Publicado: (2021)

Piperacillin/tazobactam/vancomycin: Cast nephropathy: case report
Publicado: (2022)

Piperacillin/tazobactam: Acute eosinophilic pneumonia: case report
Publicado: (2021)

Piperacillin-Tazobactam Allergies: An Exception to Usual Penicillin Allergy
por: Wong, Jane CY, et al.
Publicado: (2020)

Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
por: Martin Mena, Anthony, et al.
Publicado: (2023)

Drug Fever Due to Piperacillin/Tazobactam Loaded into Bone Cement
por: Park, Hyun Bum, et al.
Publicado: (2011)

Cefoxitin vs. Piperacillin/Tazobactam for Acute Appendicitis in Pediatric Patients
por: Paek, Hana, et al.
Publicado: (2017)

Hematologic Adverse Effects of Prolonged Piperacillin-Tazobactam Use in Adults
por: Benli, Aysun, et al.
Publicado: (2018)

Piperacillin/tazobactam: Increased liver function tests: case report
Publicado: (2020)

Piperacillin–tazobactam induced bicytopenia in low cumulative treatment doses
por: Chen, Chien-Chou, et al.
Publicado: (2019)

Piperacillin/tazobactam/vancomycin: Clostridium difficile colitis: case report
Publicado: (2021)

Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini‐review and population pharmacokinetic analysis
por: Selig, Daniel J., et al.
Publicado: (2022)

In Vitro Synergy of Levofloxacin Plus Piperacillin/Tazobactam against Pseudomonas aeruginosa
por: Chachanidze, Vladimir, et al.
Publicado: (2009)

Piperacillin/tazobactam administered by continuous or intermittent infusion for the treatment of nosocomial pneumonia
por: Lorente, L, et al.
Publicado: (2009)

Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam
por: Rodriguez, Carlos A., et al.
Publicado: (2016)

Severe piperacillin–tazobactam‐induced hemolysis in a cystic fibrosis patient
por: Kerkhoff, Andrew D., et al.
Publicado: (2017)

2407. Emerging Piperacillin/Tazobactam Resistance in Escherichia coli and Klebsiella sp.
por: Suseno, Mira, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0gciuvtklu21h50nl3sbi39oq9